MEDX Xelerator Approves New “X Lab” Project to Improve Treatment of Peripheral Venous Disease Care, Forms VeinWay Under CEO Jordan Pollack: Peripheral Device Genius

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

December 4, 2020

MEDX Xelerator, is an Israel-based medical device and digital health incubator who recently announced the approval of its latest “X Lab” project focused on treating peripheral venous disease (PVD). The newly formed company, VeinWay, will be headed by experienced biomedical engineer and freshman entrepreneur Jordan Pollack.

MEDX Xelerator notes VeinWay recently received a grant of over $35K from The Ideation (Tnufa) Incentive Program of The Israel Innovation Authority. The goal of the grant is to support the company in reaching proof of concept and business feasibility.

MEDX Xelerator’s X Lab program was established to cultivate promising innovation at its earliest stage, supporting and helping inventors and entrepreneurs cultivate their ideas addressing complex unmet clinical needs. By providing resources, industry expertise, and wide-spread networking capabilities, MEDX supports its X Lab entrepreneurs in developing a proof-of-concept, and then, if a proof of concept is demonstrated, advancing these early-stage startups to enter the formal incubator program.

“It’s a great privilege to be inducted into the X Lab program and gain the full support and guidance of the extended MEDX team,” said Jordan Pollack, X Lab Entrepreneur in Residence and CEO of VeinWay. “I am excited to collaborate with MEDX’s experienced and well-connected leadership to leverage my peripheral vasculature expertise and together, to provide the industry with much-needed innovation to improve care for patients with PVD.”

Pollack has spent his career building his engineering experience within the medical device field, having held multiple positions in established, globally traded companies including Boston Scientific and InspireMD. Pollack was also the President and CEO of his own startup, LiveSAVR Solutions, which developed a novel smart guidewire for accurate placement of transcatheter aortic valves. Pollack holds master’s and bachelor’s degrees in biomedical engineering from the University of Michigan.

“Our relationship with Jordan stems back to a joint project with Boston Scientific, where we first noticed his extensive knowledge of the peripheral venous industry and entrepreneurial spirit,” said Shai Policker, CEO of MEDX Xelerator. “Following his recent immigration to Israel, we are delighted to play a role in guiding and nurturing his growth and development within this field, and are happy to assist in Jordan’s goal of elevating the standard of care for PVD management.”



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.